Navigation Links
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Date:4/15/2008

Clinical studies show Treximet provided significantly more patients

migraine pain relief compared to sumatriptan 85 mg

LONDON, April 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and POZEN Inc. (Nasdaq: POZN) announced today that the FDA has approved Treximet for the acute treatment of migraine attacks with or without aura in adults. Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines pioneered by GSK, and an anti-inflammatory pain reliever in a single tablet.

Treximet contains 85 mg sumatriptan, formulated with RT Technology(TM), and 500 mg naproxen sodium. Sumatriptan is the active ingredient in Imitrex(R) Tablets, available in 25 mg, 50 mg and 100 mg strengths. In clinical trials, Treximet provided a significantly greater percentage of patients migraine pain relief at two hours compared to sumatriptan 85 mg or naproxen sodium 500 mg alone. In addition, Treximet provided more patients sustained migraine pain relief from two to 24 hours compared to the individual components.

"Migraine patients want their medicine to work early, and to continue to provide relief," said Dr. Stephen Silberstein, professor of neurology and director of the Jefferson Headache Center at Thomas Jefferson University and an investigator who participated in clinical trials. "The FDA approval of Treximet is good news for migraine patients because clinical trials showed that Trexime
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained With Naproxen Sodium
2. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
3. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
4. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
5. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
7. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
10. Newly Approved HIV Drug Shows Great Promise
11. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Novastem, a leader in regenerative medicine, ... its study for ischemic stroke at Clinica Santa ... strokes account for 87 percent of all stroke ... the study, entitled "Internal Research Protocol in Combination ... Cells and Intrathecal Administration of Neural Stem Cells ...
(Date:12/24/2014)... Pa. , Dec. 24, 2014  Commonwealth Cornerstone Group ... Markets Tax Credits transaction on Tuesday to help fund the ... Network (PHN) in Sharon . ... in Pennsylvania . It is the largest ... with more than 150 people on staff. Currently, ...
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... OMER ) today announced that its exclusive license to ... been amended to include addiction and compulsive disorders in the ... Company,s discovery of a previously unknown link between PDE7 and ... it also is the first to link PDE7 to any ...
... BRUNSWICK, N.J. and LEIDEN, Netherlands, Feb. 22, 2011 Johnson ... (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) ... offer for Crucell N.V. (Crucell) and has declared the offer ... center for vaccines within the Johnson & Johnson pharmaceuticals group. ...
Cached Medicine Technology:Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 3Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 4Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 2Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 3Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 4Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 5Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 6Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 7Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 8
(Date:12/24/2014)... 2014 Over 700 toys, that’s what ... communities. That is 700 smiling little faces this holiday ... over $6000 in monetary donations was given to the ... the expenses they incur through the year. Some of ... A Child's Haven , Shrine's Children's Hospitals, Toys for ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
(Date:12/24/2014)... York, New York (PRWEB) December 24, 2014 ... to mount in a mass tort litigation currently underway ... LLP reports. As of December 24, 2014, court ... the proceeding on behalf of individuals who developed gynecomastia ... its use. Data from the Court indicates that this ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Dr. ... announced the expansion of his practice and med-spa with ... the practice’s growing list of cosmetic treatments and services. ... solution into the skin,” says Dr. Ho. “As a ... changes such as wrinkles, sun spots, discolorations or blemishes.” ...
(Date:12/24/2014)... Today, UWDress.com, the famous women’s dress supplier, has ... launched a site-wide wedding gown promotion. , For ... a more unexpected way, the collection should be a great ... global market, and they are available with custom service. , ... discounted prices, up to 75% off; most of them come ...
Breaking Medicine News(10 mins):Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2
... WAUSAU, Wis., July 8 Like an estimated 5 million ... condition that greatly increases the risk of stroke and causes ... , , Aspirus cardiovascular surgeon John Johnkoski, M.D., ... Simonis to correct the condition that plagued the Rosholt resident ...
... with service, study finds , WEDNESDAY, July 8 (HealthDay ... new study says soldiers who need electrical spinal cord ... to return to active duty. , In electrical spinal ... help disrupt nerve signals for pain. The procedure, an ...
... SOUTH SAN FRANCISCO, Calif., July 8 ... a teleconference at 11:00 a.m. Eastern Time tomorrow, Thursday, ... deal in the past six months, this time for ... currently in Phase II clinical development for the prevention ...
... work conditions may be to blame for the decline in ... study published in the latest issue of the Annals ... are associated with stress, burnout and intent to leave for ... assistant professor in the department of medicine, Loyola University Chicago ...
... Foundation of America, Inc. (LFA) is accepting letters of intent ... transplantation research in humans as a treatment for lupus, and ... affect the health-related quality of life of children, adolescents and ... will award one $100,000 grant for adult stem cell research. ...
... LoJack Corporation (Nasdaq: LOJN ) and ... LoJack SafetyNet System and Project Lifesaver Program has helped to rescue ... Alzheimer,s or dementia who had wandered over the past month. ... with cognitive conditions at risk of wandering, and is a particularly ...
Cached Medicine News:Health News:Advanced Heart Procedure Treats Growing Problem 2Health News:Advanced Heart Procedure Treats Growing Problem 3Health News:Portola Pharmaceuticals to Host Conference Call at 11:00 a.m. Eastern Time Tomorrow to Discuss Betrixaban Partnership and Provide Corporate Update 2Health News:Health clinic conditions may be to blame for decrease in primary care physicians 2Health News:Lupus Foundation of America Accepting Letters of Intent for Research Grants on Adult Stem Cell Research and Health-Related Quality of Life in Pediatric Lupus 2Health News:LoJack SafetyNet and Project Lifesaver Help Rescue Clients Afflicted With Alzheimer's/Dementia Who Wandered 2Health News:LoJack SafetyNet and Project Lifesaver Help Rescue Clients Afflicted With Alzheimer's/Dementia Who Wandered 3Health News:LoJack SafetyNet and Project Lifesaver Help Rescue Clients Afflicted With Alzheimer's/Dementia Who Wandered 4Health News:LoJack SafetyNet and Project Lifesaver Help Rescue Clients Afflicted With Alzheimer's/Dementia Who Wandered 5
... The CKX microscopes utilize ... improved visibility and operability in ... a cost-effective inverted microscope suited ... range of fields--from tissue culture ...
The simplest, neatest, most efficient anti-theft system for frames and sunwear. Available in 3 colors Black, Matte aluminum, and Bronze. Fits with any style or color of furniture. Safe, simple, easy...
69" 5 shelves electric rotating display with gunmetal grey frame. Lead time 6-8 weeks....
1 Frame clear base post with transparent Eyevee 2.0 Clip....
Medicine Products: